ALLK News and Press, Allakos Inc. From 03/04/24

Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...

– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model – SAN CARLOS, C...

–  Data provide insights on the signaling pathways involved with AK006 mast cell inhibition – – AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Allakos Inc....

2024-01-17 11:52:02 ET More on Allakos ELAB, KIND and RLX among pre-market losers Allakos crashes on restructuring plans Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos For ...

2024-01-17 09:00:32 ET Losers: DatChat DATS -32% plans to sell shares through public offering . Acurx Pharmaceuticals ( NASDAQ: ACXP ) -24% announces positive comparative Microbiology and Microbiome data for Ibezapolstat from phase 2b clinical trial in CDI ...

NEW YORK, NY / ACCESSWIRE / January 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK). Investors who purchased Allakos securities are encouraged to obtain additional information a...

2024-01-16 12:55:23 ET Gainers: Phunware ( PHUN ) +258% . DatChat ( DATS ) +61% . SEALSQ Corp ( LAES ) +40% . HomeStreet ( HMST ) +39% . Altisource Asset Management Corp ( AAMC ) +37% . Jin Medical International Ltd ( ZJYL ...

2024-01-16 07:40:49 ET More on Allakos Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos For further details see: Allakos crashes on restructuring plans

Existing cash to fund planned ongoing operations into mid-2026 AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteers a randomized, double-blind, placebo-controlled trial in patients with CSU...

– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE...